Beijing Wantai Biological Pharmacy Enterprise 대차 대조표 상태

재무 상태 기준 확인 5/6

Beijing Wantai Biological Pharmacy Enterprise 의 총 주주 지분은 CN¥12.6B 이고 총 부채는 CN¥267.0M, 이는 부채 대 자기자본 비율을 2.1% 로 가져옵니다. 총자산과 총부채는 각각 CN¥14.7B 및 CN¥2.1B 입니다.

주요 정보

2.1%

부채 비율

CN¥267.03m

부채

이자 보상 비율	n/a
현금	CN¥5.50b
주식	CN¥12.61b
총 부채	CN¥2.13b
총 자산	CN¥14.74b

최근 재무 상태 업데이트

These 4 Measures Indicate That Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Is Using Debt Reasonably Well

Jul 22

Recent updates

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) Analysts Are Reducing Their Forecasts For This Year

Jul 26

These 4 Measures Indicate That Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Is Using Debt Reasonably Well

Jul 22

Some Investors May Be Willing To Look Past Beijing Wantai Biological Pharmacy Enterprise's (SHSE:603392) Soft Earnings

Apr 04

Things Look Grim For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) After Today's Downgrade

Apr 02

Earnings Tell The Story For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) As Its Stock Soars 27%

Feb 28

재무 상태 분석

단기부채: 603392 의 단기 자산 ( CN¥9.0B )이 단기 부채( CN¥1.9B ).

장기 부채: 603392 의 단기 자산( CN¥9.0B )이 장기 부채( CN¥180.9M ).

부채 대 자본 내역 및 분석

부채 수준: 603392 총 부채보다 더 많은 현금을 보유하고 있습니다.

부채 감소: 603392 은 5년 전에 마이너스 주주 지분을 가졌으나 지금은 플러스이므로 개선되었습니다.

부채 범위: 603392 의 부채는 영업 현금 흐름 ( 316.3% )에 의해 잘 충당되었습니다.

이자 보장: 603392 의 부채에 대한 이자 지급이 EBIT에 의해 잘 충당되었는지 판단할 데이터가 부족합니다.

Beijing Wantai Biological Pharmacy Enterprise 대차 대조표 상태

재무 상태 기준 확인 5/6

주요 정보

최근 재무 상태 업데이트

These 4 Measures Indicate That Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Is Using Debt Reasonably Well

Recent updates

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. to Report Q3, 2024 Results on Oct 25, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Consensus EPS estimates fall by 26%

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) Analysts Are Reducing Their Forecasts For This Year

Price target decreased by 9.7% to CN¥63.10

Consensus revenue estimates fall by 15%

These 4 Measures Indicate That Beijing Wantai Biological Pharmacy Enterprise (SHSE:603392) Is Using Debt Reasonably Well

Consensus EPS estimates increase by 16%, revenue downgraded

Price target decreased by 7.1% to CN¥69.85

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. to Report First Half, 2024 Results on Aug 23, 2024

Consensus EPS estimates fall by 26%

First quarter 2024 earnings released: EPS: CN¥0.10 (vs CN¥0.99 in 1Q 2023)

Investor sentiment improves as stock rises 15%

Some Investors May Be Willing To Look Past Beijing Wantai Biological Pharmacy Enterprise's (SHSE:603392) Soft Earnings

Consensus revenue estimates fall by 52%

Things Look Grim For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) After Today's Downgrade

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. to Report Q1, 2024 Results on Apr 26, 2024

Full year 2023 earnings: EPS and revenues miss analyst expectations

Earnings Tell The Story For Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) As Its Stock Soars 27%

Investor sentiment deteriorates as stock falls 15%

Price target increased by 11% to CN¥69.43

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. to Report Fiscal Year 2023 Results on Mar 29, 2024

Investor sentiment improves as stock rises 24%

Consensus revenue estimates decrease by 35%

Third quarter 2023 earnings released: EPS: CN¥0.085 (vs CN¥0.99 in 3Q 2022)

Price target decreased by 19% to CN¥78.50

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) announces an Equity Buyback for CNY 400 million worth of its shares.

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Price target decreased by 10% to CN¥97.50

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Full year 2022 earnings: EPS in line with expectations, revenues disappoint

Investor sentiment deteriorated over the past week

Investor sentiment improved over the past week

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: CN¥1.38 (vs CN¥0.39 in 3Q 2021)

Second quarter 2022 earnings released: EPS: CN¥1.55 (vs CN¥0.79 in 2Q 2021)

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. (SHSE:603392) announces an Equity Buyback for CNY 400 million worth of its shares.

Investor sentiment improved over the past week

Investor sentiment deteriorated over the past week

No independent directors

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Investor sentiment improved over the past week

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Third quarter 2021 earnings released: EPS CN¥0.56 (vs CN¥0.38 in 3Q 2020)

Second quarter 2021 earnings released: EPS CN¥1.15 (vs CN¥0.29 in 2Q 2020)

Consensus forecasts updated

Price target increased to CN¥339

First quarter 2021 earnings released: EPS CN¥0.67 (vs CN¥0.18 in 1Q 2020)

Full year 2020 earnings released: EPS CN¥1.62 (vs CN¥0.54 in FY 2019)

Full year 2020 earnings released: EPS CN¥1.62 (vs CN¥0.54 in FY 2019)

Revenue and earnings beat expectations

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. to Report Fiscal Year 2020 Results on Mar 26, 2021

New 90-day high: CN¥338

New 90-day high: CN¥290

New 90-day high: CN¥221

New 90-day low: CN¥171

Third quarter earnings released

New 90-day low: CN¥173

First half earnings released

New 90-day high - CN¥243

Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. to Report First Half, 2020 Results on Aug 21, 2020

재무 상태 분석

부채 대 자본 내역 및 분석

대차 대조표

건강한 기업 발견하기